Kokuma chose Cosmetic 360 as the platform to reveal its very first ingredients portfolio to the beauty market. The company’s tagline, "tone as your like" aptly sums up the biotech’s debut patented ingredients: TONASULIKE-P is a skin-tone enhancer formulated to bring a lasting glow to the skin by “stimulating” the skin’s melanin content, but without calling for exposure to UVs. "The idea is for TONASULIKE-P to be integrated into the consumer’s daily skincare, makeup and even suncare routine," remarks Alexandre Jouve, the company’s CEO and Co-founder, adding that it is suited to a variety of textures, including serums, lotions, creams, emulsions and BB cream formulas. The effects begin to be visible in around two weeks.
TONASULIKE-D could be described as the flip side of TONASULIKE-P: it is designed to brighten the skin and reduce age spots by lowering the production of melanin—visible effects here happen at a somewhat slower rate of around six weeks, according to tests overseen by the company's Chief Scientific Officer and Co-founder Yannick Quesnel. Kokuma’s in-vitro tests have shown melanin content to be reduced by up to 86%. "As compared to anti-aging formulas targeting wrinkles, which has been a hotbed of research over the last few years, there have been very few advances in depigmentation. Not to mention that some of the key ingredients in this space have been banned in numerous markets. As a result, we believe there is a real need for what our ingredients are offering, and the results speak for themselves," notes Olivier Fontaine, Board Member and Operational Advisor.
For Kokuma, these ingredients’ efficacy sets them apart. "We’ve obtained clinical proof that is truly game changing for these two respective markets," concludes Jouve.
